Hans-Christoph Diener1, Christian Gerloff2, David E Thaler3, Jochen Wöhrle4. 1. Senior Professor of Clinical Neurosciences, Medical Faculty of the University Duisburg-Essen, Essen, Germany. hans.diener@uk-essen.de. 2. Department of Neurology, University Medical Center Eppendorf (UKE), Hamburg, Germany. 3. Department of Neurology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA. 4. Department of Internal Medicine II - Cardiology, University Ulm Germany, Ulm, Germany.
Abstract
PURPOSE OF REVIEW: This review summarises the results of randomised trials comparing closure of patent foramen ovale (PFO) with antithrombotic therapy in patients with cryptogenic stroke. RECENT FINDINGS: Initially, three randomised trials failed to show superiority of PFO closure over antithrombotic therapy in patients with cryptogenic stroke. Three recently performed trials and the prolongation of an earlier trial provided evidence that PFO closure in patients with cryptogenic stroke and an age range of 18-60 years is superior to stroke prevention with antiplatelet therapy. PFO closure was not superior to anticoagulation. Anticoagulation, however, has a higher long-term bleeding risk. PFO closure could result in atrial fibrillation (AF) in a small number of patients. In most patients, AF was transient in duration. Optimal patient selection requires future research. In patients with cryptogenic stroke aged < 60 years, PFO closure is superior to antiplatelet therapy in the prevention of recurrent stroke.
PURPOSE OF REVIEW: This review summarises the results of randomised trials comparing closure of patent foramen ovale (PFO) with antithrombotic therapy in patients with cryptogenic stroke. RECENT FINDINGS: Initially, three randomised trials failed to show superiority of PFO closure over antithrombotic therapy in patients with cryptogenic stroke. Three recently performed trials and the prolongation of an earlier trial provided evidence that PFO closure in patients with cryptogenic stroke and an age range of 18-60 years is superior to stroke prevention with antiplatelet therapy. PFO closure was not superior to anticoagulation. Anticoagulation, however, has a higher long-term bleeding risk. PFO closure could result in atrial fibrillation (AF) in a small number of patients. In most patients, AF was transient in duration. Optimal patient selection requires future research. In patients with cryptogenic stroke aged &lt; 60 years, PFO closure is superior to antiplatelet therapy in the prevention of recurrent stroke.
Authors: Jeffrey L Saver; John D Carroll; David E Thaler; Richard W Smalling; Lee A MacDonald; David S Marks; David L Tirschwell Journal: N Engl J Med Date: 2017-09-14 Impact factor: 91.245
Authors: John D Carroll; Jeffrey L Saver; David E Thaler; Richard W Smalling; Scott Berry; Lee A MacDonald; David S Marks; David L Tirschwell Journal: N Engl J Med Date: 2013-03-21 Impact factor: 91.245
Authors: Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly Journal: Lancet Neurol Date: 2014-04 Impact factor: 44.182
Authors: David M Kent; Robin Ruthazer; Christian Weimar; Jean-Louis Mas; Joaquín Serena; Shunichi Homma; Emanuele Di Angelantonio; Marco R Di Tullio; Jennifer S Lutz; Mitchell S V Elkind; John Griffith; Cheryl Jaigobin; Heinrich P Mattle; Patrik Michel; Marie-Louise Mono; Krassen Nedeltchev; Federica Papetti; David E Thaler Journal: Neurology Date: 2013-07-17 Impact factor: 9.910
Authors: Ton Kuijpers; Frederick A Spencer; Reed A C Siemieniuk; Per O Vandvik; Catherine M Otto; Lyubov Lytvyn; Hassan Mir; Albert Y Jin; Veena Manja; Ganesan Karthikeyan; Elke Hoendermis; Janet Martin; Sebastian Carballo; Martin O'Donnell; Trond Vartdal; Christine Baxter; Bray Patrick-Lake; Joanie Scott; Thomas Agoritsas; Gordon Guyatt Journal: BMJ Date: 2018-07-25
Authors: Hassan Mir; Reed Alexander C Siemieniuk; Long Ge; Farid Foroutan; Michael Fralick; Talha Syed; Luciane Cruz Lopes; Ton Kuijpers; Jean-Louis Mas; Per O Vandvik; Thomas Agoritsas; Gordon H Guyatt Journal: BMJ Open Date: 2018-07-25 Impact factor: 2.692
Authors: Katharina Feil; Johanna Heinrich; Aenne S von Falkenhausen; Regina Becker; Clemens Küpper; Katharina Müller; Dennis C Thunstedt; Moritz F Sinner; Stefan Kääb; Lars Kellert Journal: Case Rep Neurol Date: 2020-01-29